WallStSmart

Alcon AG (ALC)vsBioLife Solutions Inc (BLFS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 10710% more annual revenue ($10.40B vs $96.21M). ALC leads profitability with a 9.4% profit margin vs -4.8%. ALC appears more attractively valued with a PEG of 1.70. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

BLFS

Avoid

33

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 4.0Quality: 6.5
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued

Intrinsic value data unavailable for BLFS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

BLFS2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
63.9%10/10

Revenue surging 63.9% year-over-year

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

BLFS4 concerns · Avg: 2.3/10
Market CapQuality
$951.51M3/10

Smaller company, higher risk/reward

PEG RatioValuation
65.382/10

Expensive relative to growth rate

Return on EquityProfitability
-3.4%2/10

ROE of -3.4% — below average capital efficiency

EPS GrowthGrowth
-13.9%2/10

Earnings declined 13.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : BLFS

The strongest argument for BLFS centers on Revenue Growth, Price/Book. Revenue growth of 63.9% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : BLFS

The primary concerns for BLFS are Market Cap, PEG Ratio, Return on Equity.

Key Dynamics to Monitor

ALC profiles as a value stock while BLFS is a hypergrowth play — different risk/reward profiles.

BLFS carries more volatility with a beta of 1.94 — expect wider price swings.

BLFS is growing revenue faster at 63.9% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (49/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

BioLife Solutions Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.

Want to dig deeper into these stocks?